| Predicate |
Object |
| contentType |
Journal Article|Research Support, N.I.H., Extramural|Review |
| endingPage |
772 |
| issn |
1744-6872 |
| issueIdentifier |
11 |
| pageRange |
769-772 |
| publicationName |
Pharmacogenetics and Genomics |
| startingPage |
769 |
| hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a1ebfe17b0713ecaf89801f0370c078d |
| isSupportedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_6efd070ff5a55956273cbae0835de8a9
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_a31e0015f3389413b018a2d500973455
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b74aeddf68e09dc575bc8461a37526d6 |
| bibliographicCitation |
Sangkuhl K, Klein TE, Altman RB. PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769–72. PMID: 21546862; PMCID: PMC3349993. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d9fc464e349bf2a52885073c6fbe604b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c1d8811a0fff2aa2b34d1465e347d166
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5bae64898beae636b2fcfb665b2bfb76 |
| date |
201111 |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/21546862
https://doi.org/10.1097/fpc.0b013e328346063f
https://pubmed.ncbi.nlm.nih.gov/PMC3349993 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1744-6872
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32413 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
PharmGKB summary: citalopram pharmacokinetics pathway |
| discusses |
http://id.nlm.nih.gov/mesh/M0023529
http://id.nlm.nih.gov/mesh/M0026372 |